Krabbe disease and the screen that runs out of time

The intervention window in infantile Krabbe disease is measured in weeks. Hematopoietic stem cell transplantation, the only currently approved disease-modifying intervention, must be performed before the child becomes symptomatic. The age at which infantile-onset Krabbe becomes symptomatic ranges across a few months. Newborn screening identifies affected infants on the dried blood spot. Confirmation testing, family counseling, donor identification, and transplant scheduling have to happen on a timeline the disease will not allow to slip.

This is the screen where the clinical question is whether the system catches the child in time, given that the assay reliably catches the disease.

What Krabbe is

Krabbe disease, also called globoid cell leukodystrophy, is an autosomal recessive lysosomal storage disorder caused by deficiency of galactosylceramidase, GALC, encoded by GALC on chromosome 14q31. GALC degrades galactosylceramide, a major component of myelin, and psychosine, a related sphingolipid. When GALC activity fails, psychosine accumulates and is toxic to oligodendrocytes and Schwann cells. Myelin formation fails in central and peripheral nerves. The disease is a leukodystrophy with peripheral neuropathy.

The clinical course depends on age of onset. Infantile-onset Krabbe, accounting for the majority of cases, presents between two and six months of age with irritability, feeding difficulties, hypertonia and arching, regression of acquired motor skills, seizures, and a relentless neurological decline. Most affected infants die in the first or second year of life without intervention. Late-infantile, juvenile, and adult-onset forms have slower courses with more variable presentations.

Reported live-birth incidence of classic infantile Krabbe is roughly 1 in 100,000 to 1 in 250,000 in unselected populations. Higher rates have been documented in specific founder populations including some Druze and Christian Arab populations, several Old Order Mennonite communities, and isolated regions in southern Italy.

Detection and the screening problem

GALC enzyme activity is measurable on the dried blood spot. New York added Krabbe to its newborn screening panel in 2006, the first state to do so, and the experience of the New York program is the most extensively documented natural-history-of-screening data for Krabbe. Several other states have added Krabbe since.

The screening problem is a combination of three issues. First, GALC enzyme activity on the dried blood spot has incomplete predictive value: a low result identifies a population enriched for affected infants but also includes carriers and infants with low pseudodeficiency activity who will not develop disease. Second, distinguishing infantile-onset cases from later-onset cases at the moment of detection is hard, because the genotype-phenotype correlation in GALC is incomplete. Third, the time required to confirm the diagnosis and arrange a transplant is long enough that some screen-detected infants become symptomatic before the procedure can occur.

Two-tier and three-tier screening protocols have evolved to manage these issues. Initial dried-blood-spot enzyme activity is followed by GALC sequencing, psychosine measurement (psychosine elevation correlates with severity and clinical course), and clinical evaluation including brain MRI and nerve conduction studies. The combined panel improves the predictive value but extends the timeline.

What treatment exists

Hematopoietic stem cell transplantation, performed before symptom onset, provides donor-derived cells that produce GALC and slow the progression of the disease. Survival and motor outcomes after pre-symptomatic HSCT are substantially better than the natural history of untreated infantile Krabbe. Transplanted children have been reported to walk independently at ages where untreated children have died. Some clinical features, particularly peripheral neuropathy and gross motor delay, are imperfectly addressed by HSCT.

HSCT after symptom onset rarely halts progression. The therapeutic window for infantile Krabbe is the period between identification on screening and the appearance of clinical signs.

Gene therapy programs for Krabbe have advanced into clinical trials. AAV-delivered GALC gene therapy and ex vivo lentiviral approaches are in development. As of 2024, no gene therapy is FDA-approved specifically for Krabbe disease.

What management looks like

For a screen-detected infant with biochemical and genetic findings consistent with infantile-onset Krabbe, the standard sequence is rapid confirmatory testing including psychosine measurement, neurology and metabolism consultation, donor search initiated through the National Marrow Donor Program or related registries, and transplantation in the first weeks of life when a suitable donor is available. The procedure carries the standard risks of allogeneic HSCT in infancy, including conditioning toxicity and graft-versus-host disease.

For infants with biochemical screening abnormalities consistent with later-onset disease or with pseudodeficiency, surveillance includes periodic neurological evaluation, MRI, nerve conduction studies, and psychosine measurement to track for evidence of disease activity. Families with later-onset variants live in extended uncertainty about whether and when symptoms will appear.

Supportive care for symptomatic Krabbe includes seizure management, feeding support, respiratory care, and palliative measures. Family support and access to specialized hospice care are part of the management of the symptomatic course.

What this looks like for a family

A baby is born in a state that screens. On day 4, the state lab reports a low GALC activity. On day 5, the family is in a metabolic genetics clinic. Confirmatory sequencing returns biallelic GALC pathogenic variants and psychosine elevation consistent with infantile-onset disease. The family meets the bone marrow transplant team. The donor search begins. The transplant is performed before the second month of life. Eight years later, the child is walking, attending school with support, and managing the residual neurological features of a disease that, without screening and transplantation, would have killed him before his second birthday.

A baby is born in a state that does not screen. Her parents notice that something is wrong when she is four months old. Imaging shows leukodystrophy. By the time the diagnosis is confirmed, she is symptomatic. The transplant window has closed. The treatment is supportive. The disease is the same disease.

The screening test is the same test in both states. The post-screen system is the part that is harder to build than the assay.